- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03919591
RSV Study in Adults 60 to 75 Years of Age
An Exploratory Pilot Study to Evaluate the Clinical Safety and Virologic Profile of an Experimental RSV Infection in Adults 60 to 75 Years of Age
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
RSV is a common virus that affects all human age groups. Typical RSV illness is identified by symptoms such as runny nose, stuffy nose, sneezing, sore throat, earache, malaise or tiredness, cough, shortness of breath, headache, muscle ache, joint ache or stiffness, chilliness and feverishness. RSV spreads easily from person to person through the eyes, nose or mouth when droplets containing the virus, such as those from coughing or sneezing, are inhaled or passed to others. Adults with risk factors, like another illness or disease, may experience an RSV illness that is more severe or lasts longer. RSV may also start a worsening of health in frail adults, people with weak immune systems, and those with chronic cardio-pulmonary disease.
No treatment or vaccine to treat or prevent RSV disease is available in the UK. Vaccination against RSV has the potential to be a highly beneficial and effective approach to reduce RSV disease in older adults as well as other high-risk adult and paediatric populations. The use of RSV human viral challenge model provides an important tool to evaluate the effectiveness of new RSV vaccines. Specifically, a RSV human viral challenge in 60 to 75-year-old individuals would enable measuring the effectiveness of RSV vaccines in a population that is thought to be less responsive to vaccines than the 18-45-year-old population.
The purpose of this study is to infect up to 74 healthy subjects aged 60 to 75 years old with RSV in a controlled quarantine environment to confirm how safe and well tolerated the use of an experimental RSV virus infection is in a population that has not previously received the virus. Additionally, the investigators will also look at various components of the subjects' blood, the lining of their noses and other samples in order to measure the effects of the virus on the body, in particularly the immune system before, during and after viral infection.
The study will consist of 3 phases: 1) Screening, 2) Quarantine and 3) Follow-up.
The enrolment of the subjects will be staggered with safety data reviews performed between groups. Each volunteer will be in the study for approximately 3 months from screening to their last scheduled clinic visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, E1 2AX
- hVIVO Services Limited
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (non-exhaustive list):
- Healthy subjects aged 60 to 75 years
- Able to give informed consent
- A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 33 kg/m2.
- In good health with no history of major medical conditions, or clinically significant test abnormalities that will interfere with subject safety as determined by the Investigator at screening evaluation
- Documented medical history either prior to entering the study and/or following medical history review by the Investigator at screening.
- Serum IgA result within normal range at screening.
- Subjects meeting the contraception criteria of the study.
Exclusion Criteria (non-exhaustive list):
- Subjects who have smoked ≥ 10 pack years (or 20 cigarettes a day for 10 years). Of those subjects that have smoked less than 10 pack years at any time, a subject will be excluded, if in the last year, he/she has smoked any number of cigarettes in the last month and/or they have used tobacco in any form or other nicotine-containing products in any form.
- Subjects who smoked in the last month prior to the study
- Females who are breastfeeding, have been pregnant within 6 months prior to the study, or have a positive pregnancy test.
- History of clinically significant or major disease that, in the opinion of the Investigator, may interfere with a subject completing the study and necessary investigations.
- A forced expiratory volume in 1 second (FEV1) < 80% predicted.
- Twelve-lead ECG recording with clinically relevant abnormalities.
- Positive HIV, Hep A, B or C test.
- Confirmed positive test for drugs of abuse.
- Presence of fever prior to the challenge.
- Evidence of vaccinations within the 4 weeks prior to the planned date of enrolment, or intention to receive any vaccination before the last scheduled visit of the study.
- Those employed or immediate relatives of those employed at hVIVO.
- Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior to the planned date of enrolment.
- Receipt of systemic glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of enrolment.
- History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks prior to enrolment.
- Any clinically significant history of large nosebleeds.
- Any significant abnormality altering the anatomy of the nose.
- History of significant/severe wheeze, respiratory symptoms resulting in hospitalisation, or known bronchial hyperreactivity to viruses.
- History of anaphylaxis-and/or severe allergic reaction.
- Use or anticipated use during the conduct of the study of concomitant medications.
- Resident of nursing home and other long-term care facilities or with close or household contact with vulnerable people for approximately 2 weeks following discharge from unit.
- History or presence of alcohol addiction.
- Any other finding that, in the opinion of the Investigator, deems the subject unsuitable for the study.
- Subjects with no detectable antibody to the challenge virus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Open Label Pilot
Open Label Pilot Study.
All subjects will receive the viral challenge inoculum.
|
Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of routine clinical assessment abnormalities reported as adverse events.
Time Frame: Safety data collected throughout the study (estimated 4 month).
|
Multiple safety clinical parameters will be used for safety evaluation:
|
Safety data collected throughout the study (estimated 4 month).
|
Number of safety laboratory assessment abnormalities reported as adverse events.
Time Frame: Safety data collected throughout the study (estimated 4 month).
|
|
Safety data collected throughout the study (estimated 4 month).
|
Number of subjects with study related Adverse Events (AEs)
Time Frame: Safety data collected throughout the study (estimated 4 month).
|
|
Safety data collected throughout the study (estimated 4 month).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral loads/shedding measurement following inoculation with RSV
Time Frame: Virology and clinical data collected throughout the study (estimated 4 month).
|
The AUC of RSV-A Memphis 37b viral load measured in nasopharyngeal swabs by qPCR (log10 copies/mL units) and by cell base infectivity assay (log10 copies/mL units).
|
Virology and clinical data collected throughout the study (estimated 4 month).
|
Duration of viral shedding.
Time Frame: Virology and clinical data collected throughout the study (estimated 4 month)
|
The time (in hours) from first detectable viral shedding to first undetectable viral shedding.
|
Virology and clinical data collected throughout the study (estimated 4 month)
|
Measurement of the total mucus weight produced.
Time Frame: Virology and clinical data collected throughout the study (estimated 4 month).
|
Total weight of nasal discharge (grams).
|
Virology and clinical data collected throughout the study (estimated 4 month).
|
Measurement of symptoms severity by self reported symptoms diary cards.
Time Frame: Symptom Diary Cards data is collected throughout the quarantine period (estimated 15 days)
|
Symptoms are recorded on a grading scale of 0 to 3.
|
Symptom Diary Cards data is collected throughout the quarantine period (estimated 15 days)
|
Measurement of the peak tympanic temperature.
Time Frame: Temperature data is collected from day 0 to day 12.
|
Time of the highest recorded tympanic temperature.
|
Temperature data is collected from day 0 to day 12.
|
Number and percentage of subjects with confirmed RSV infection.
Time Frame: Virology data collected throughout the study (estimated 4 month)
|
Confirmed infection is measured by the presence of viral shedding in nasopharyngeal swabs.
|
Virology data collected throughout the study (estimated 4 month)
|
Number and percentage of subjects with Upper and Lower Respiratory Tract Infection (URTI and LRTI)
Time Frame: Clinical data collected throughout the study (estimated 4 month)
|
URTI and LRTI are evaluated from Symptom Diary Cards and Physical Examination.
|
Clinical data collected throughout the study (estimated 4 month)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RVL-OCS-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on RSV Infection
-
Biota Pharma Europe LimitedCompletedRespiratory Syncytial Virus (RSV) InfectionUnited Kingdom
-
Gilead SciencesCompletedRespiratory Syncytial Virus (RSV)United States, Belgium, Canada, Netherlands, Australia, Germany, United Kingdom, France
-
Institute for Clinical Effectiveness, JapanGlaxoSmithKlineRecruitingAcute Disease | Respiratory Syncytial Virus (RSV) | Respiratory Viral InfectionJapan
-
Imperial College LondonRecruitingRSV InfectionUnited Kingdom
-
Bavarian NordicCompletedRSV InfectionUnited Kingdom
-
Meissa Vaccines, Inc.HvivoCompleted
-
Enanta Pharmaceuticals, InchVIVO Services LimitedCompleted
-
Hospices Civils de LyonUnknownRespiratory Syncytial Virus Infections | RSV Infection | Syncytial Virus Respiratory Infection | RSV Bronchiolitis
-
Enanta Pharmaceuticals, IncRecruitingRSV InfectionUnited States, Poland, Spain, Taiwan, Bulgaria, Argentina, Puerto Rico, Czechia, Brazil, Israel, Malaysia, Netherlands, Slovakia, South Africa
-
UMC UtrechtUniversity of Turku; University of Oxford; University of Edinburgh; Servizo Galego...Active, not recruitingRespiratory Syncytial Virus Infections | RSV Infection | RSV BronchiolitisUnited Kingdom, Netherlands, Finland, Spain
Clinical Trials on Challenge virus RSV-A Memphis 37b
-
Merck Sharp & Dohme LLCCompletedRespiratory Syncytial VirusesUnited Kingdom
-
mAbxience Research S.L.CompletedHealthy Adult ParticipantsUnited Kingdom
-
Merck Sharp & Dohme LLCCompletedRespiratory Syncytial VirusUnited Kingdom
-
Imperial College LondonNot yet recruitingRespiratory Tract InfectionsUnited Kingdom
-
Imperial College LondonWellcome TrustCompletedRespiratory Syncytial Virus Infections | Respiratory Viral InfectionsUnited Kingdom
-
Imperial College LondonMedical Research Council; Wellcome Trust; National Institute for Health Research...TerminatedInfluenza, Human | Respiratory Syncytial Virus InfectionsUnited Kingdom
-
Imperial College LondonRecruitingRSV InfectionUnited Kingdom
-
Immune Targeting Systems LtdCompleted